Delcath Systems, Inc. (DCTH)
NASDAQ: DCTH · Real-Time Price · USD
14.88
-0.66 (-4.25%)
Feb 21, 2025, 4:00 PM EST - Market closed
Delcath Systems Revenue
Delcath Systems had revenue of $11.20M in the quarter ending September 30, 2024, with 2,480.65% growth. This brings the company's revenue in the last twelve months to $22.64M, up 945.91% year-over-year. In the year 2023, Delcath Systems had annual revenue of $2.07M, down -24.05%.
Revenue (ttm)
$22.64M
Revenue Growth
+945.91%
P/S Ratio
17.24
Revenue / Employee
$297,947
Employees
76
Market Cap
475.77M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.07M | -654.00K | -24.05% |
Dec 31, 2022 | 2.72M | -836.00K | -23.52% |
Dec 31, 2021 | 3.56M | 1.91M | 115.98% |
Dec 31, 2020 | 1.65M | 66.00K | 4.18% |
Dec 31, 2019 | 1.58M | -1.83M | -53.62% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
DCTH News
- 2 days ago - Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call - Business Wire
- 8 days ago - Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma - Business Wire
- 24 days ago - Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Business Wire
- 5 weeks ago - Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 7 weeks ago - Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises - Business Wire
- 2 months ago - Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer - Business Wire
- 3 months ago - Delcath Begins Platform Expansion With Two Phase 2 Trials - Seeking Alpha